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Salt-dependent Blood Pressure 
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Hypertension is one of the most important, preventable causes of premature morbidity and mortality 
in the developed world. Aldosterone is a major mineralocorticoid hormone that plays a key role in the 
regulation of blood pressure and is implicated in the pathogenesis of hypertension and heart failure. 
Aldosterone synthase (AS, cytochrome P450 11B2, cyp11B2) is the sole enzyme responsible for the 
production of aldosterone in humans. To determine the effects of increased expression of human 
aldosterone synthase (hAS) on blood pressure (BP), we established transgenic mice carrying the hAS 
gene (cyp11B2). We showed that hAS overexpression increased levels of aldosterone in hAS+/− mice. On 
high salt diet (HS), BPs of hAS+/− mice were significantly increased compared with WT mice. Fadrozole 
(an inhibitor of aldosterone synthase) treatment significantly reduced BPs of hAS+/− mice on HS. This 
is the first time overexpression of AS in a transgenic mouse line has shown an ability to induce HP. 
Specifically inhibiting AS activity in these mice is a promising therapy for reducing hypertension. This 
hAS transgenic mouse model is therefore an ideal animal model for hypertension therapy studies.
Hypertension (HP) is a polygenic and multifactorial disease that has high incidence not only in the developed 
countries, but also in developing countries. Researchers have found that the number of adults with hypertension 
more than doubled from 1995 to 20051. Furthermore, Kearney and colleagues predict that there will be a relative 
increase of 24% in the prevalence of hypertension in developed countries from 2000 to 20252.
Aldosterone, the principal mineralocorticoid in humans, is produced in the zona glomerulosa of the adrenal 
cortex by aldosterone synthase (CYP11B2). As a key component of the renin-angiotensin-aldosterone system, 
aldosterone acts primarily at the renal distal convoluted tubules as a critical regulator of fluid and electrolyte 
homeostasis. The primary secretagogues that stimulate aldosterone biosynthesis are angiotensin II (AngII), 
adrenocorticotropic hormone (ACTH), and potassium. They all elevate cytoplasmatic calcium levels and promote 
activation of steroidogenic enzymes including aldosterone synthase (AS or 18-hydroxylase)3. It suggests that AS 
encoded by the CYP11B2 gene may contribute to dysregulation of aldosterone synthesis4, 5.
Conn initially described that primary aldosteronism (PA) proved the existence of a direct relationship 
between elevated levels of aldosterone and the development of hypertension6. Recent data indicated that PA is 
present in up to 15% individuals with hypertension7, 8. Given the roles that aldosterone plays in causing hyper-
tension and promoting vascular, renal, and myocardial disease9–12, blocking aldosterone production could be one 
option for lowering blood pressure (BP) and mitigating the target-organ damage associated with hypertension13, 
14. Inhibition of aldosterone synthase is currently being investigated as a medical treatment for hypertension, 
heart failure, and renal disorders15. For PA, with the exception of the small proportion of patients with familial 
hyperaldosteronism type I, the underlying genetic and molecular basis of the disease remains largely unknown, 
particularly the role of aldosterone synthase in the pathogenic mechanism of primary aldosteronism-related 
hypertension is currently not quite clear. Two reported AS transgenic mouse lines have demonstrated either no 
or modest 10-mm Hg higher blood pressure on the high-salt diet than on the low-salt diet (117 ± 3 mm Hg vs. 
107 ± 3 mm Hg) and wild-type mice on either diet16, 17. Therefore, it is necessary to develop a new AS transgenic 
mouse line that can demonstrate aldosterone-mediated HP symptom by markedly inducing BP in mice treated 
with high salt. Development of experimental models of PA and hypertension allow dissection and isolation of var-
ious factors associated with regulation of blood pressure, inheritance of hypertensive traits, and cellular responses 
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to injury. The mouse model with AS overexpression can be used to confirm and define functional relevance of the 
hAS gene that are known or suspected to be involved in the regulation of aldosterone secretion and HP. Moreover, 
the AS transgenic mouse model can aid in the identification of novel gene products that have not yet been identi-
fied to play a role in PA and hypertension.
In this study, we have successfully established a transgenic mouse model carrying human aldosterone synthase 
gene (cyp11B2) under the control of cyp11B1 promoter and found increased expression of hAS induces BP in this 
mouse. Significantly high serum levels of human aldosterone and high-salt-induced hypertension were observed 
in this mouse model. Interestingly, the serum level of aldosterone and high-salt-induced hypertension could be 
reduced by fadrozole in these mice. Our data suggest that AS levels are likely to affect BP responds to changes in 
dietary salt and aldosterone, and this hAS overexpression mouse line may be a useful model to study AS-mediated 
PA, hypertension, and possibly chronic kidney disease and heart failure.
Results
Generation of cyp11B1-hAS transgenic mice. To study whether AS was a therapeutic target for 
PA-related hypertension, we generated a transgenic mouse line expressing the hAS coding region (+4–+1115) 
under the control of the human cyp11B1 promoter (pCYP11B1 (−2015–+3))18 (Fig. 1A). This promoter was 
shown to target gene expression in the adrenal cortex19, 20. Figure 1B showed a ~400-fold increase of the hAS 
mRNA in adrenal glands of hAS+/− mouse compared with age-matched WT mouse. The significant amounts 
of hAS mRNA were also detected in the brain cortex (56% of mRNA levels present in adrenal glands) and hip-
pocampus (53% of mRNA levels in adrenal glands) of hAS+/− mouse (Fig. 1C).
General Characteristics of hAS+/− and WT Mice. All hAS+/− mice showed normal health, growth, 
and fertility for a year (average 6 pups/litter, ~40 breeding pairs in Indiana University) as compared to WT 
mice. Postnatal development and basic phenotype parameters were similar in both TG line and wild type mice 
(n > 100/group). The results also showed that differences in the genotypes did not significantly affect weights of 
body, adrenal gland, heart, and kidney (n = 8/group, Table 1).
hAS overexpression increased levels of aldosterone in hAS+/− mice. In order to check the effect 
of hAS overexpression on the levels of aldosterone in mice, the serum and urine levels of aldosterone were tested 
by ELISA. On normal sodium diet (NS), the serum level of aldosterone in hAS+/− mice was 299.0 ± 67.2 pg/ml, 
increased markedly (~2-fold) as compared to 123.8 ± 38.7 pg/ml in WT mice (n = 4, p < 0.01). High sodium 
diet (HS, 4% NaCl, Harland Teklad (2018)) suppressed serum level of aldosterone significantly in WT mice to 
12.4 ± 6.3 pg/ml (n = 4, p < 0.01). However, serum aldosterone level was slightly decreased in HS hAS+/− mice 
(227.7 ± 67) but without statistical significance and it was much greater than HS WT mice (Fig. 2A). On NS, the 
urine levels of aldosterone in WT (1123.3 ± 234.9 pg/ml) and hAS+/− (1227.7 ± 297.1 pg/ml) mice were sim-
ilar. Urine aldosterone level of WT mice with HS was significantly reduced to 277.3 ± 276.4 pg/ml. However, 
hAS overexpression suppressed HS-induced urine aldosterone reduction in hAS+/− mice (877.2 ± 389.1 pg/ml) 
(Fig. 2B).
Corticosterone and aldosterone share the first part of their biosynthetic pathways. The last part are mediated 
either by the aldosterone synthase (for aldosterone) or by the 11β-hydroxylase (for corticosterone). To test the 
effect of hAS overexpression on the level of corticosterone, the serum level of corticosterone was tested by ELISA. 
Figure 1. Generation of hAS transgenic mice. (A) Scheme of the cyp11B1-hAS fragment containing the human 
cyp11B1 promoter (pCYP11B1 (−2015–+3)) and the human hAS coding sequence (cDNA, +4–+1515). (B) 
Detection of hAS mRNA levels in adrenal glands of hAS+/− transgenic mice by RT-PCR. (C) Detection of hAS 
mRNA levels in adrenal gland, brain cortex and hippocampus of hAS+/− transgenic mice by RT-PCR.
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The serum corticosterone levels did not show significant changes under hAS overexpression with either normal 
sodium diet or high sodium diet (Fig. 2C).
High-salt induced hypertension in hAS+/− mice. The altered salt diets (NS, and HS) did not signif-
icantly affect the BPs of WT mice (Fig. 3). In contrast, the dietary salt affected the BPs of hAS+/− mice. On a 
1 month treatment with the HS diet, the BPs of hAS+/− mice were significantly increased compared with WT 
mice (SBP: 135 ± 14.1 mmHg versus 109 ± 8.8 mmHg; DBP: 111 ± 13.9 mmHg versus 87 ± 8.0 mmHg, P < 0.001, 
n = 9) (Fig. 3A). With the continuation of the HS diet for a total of 3 months, BPs of hAS+/− mice were still sig-
nificantly higher than WT mice (SBP: 137 ± 12.6 mmHg versus 101 ± 9.1 mmHg; DBP: 113 ± 19.5 mmHg versus 
80 ± 8.3 mmHg, P < 0.001, n = 9) (Fig. 3B).
Electrolytes, renin, hematocrit, urine pH, and kidney gene expressions in WT and hAS+/− 
mice. In order to further characterize the hAS+/− mice, we examined plasma and urinary levels of Na+ and K+ 
in both WT and AS+/− mice (Table 2). As expected, plasma levels of Na+ were significantly higher in hAS+/− mice 
as compared to WT mice. In contrast, plasma levels of K+ were significantly lower in hAS+/− mice as compared to 
WT mice. Although HS diets did not increase plasma levels of Na+ in both hAS+/− and WT mice, in hAS+/− mice, 
HS significantly reduced K+ levels in hAS+/− mice. Additionally, consistent to previous report21, plasma renin 
activities in both hAS+/− and WT mice were markedly decreased in HS fed mice as compared to NS fed mice. In 
both NS and HS fed mice, hAS+/− showed significantly higher plasma renin activity than WT mice. There were 
slightly but significant reduced hematocrit in NS fed hAS+/− mice as compared to NS fed mice and HP induced 
by HS was accompanied with significantly increased hematocrit in hAS+/− mice as compared to WT mice without 
induced HP. In urine, hAS+/− mice showed significantly reduced levels of Na+ than WT mice. As predicted, HS 
stimulated Na+ excretions and decreased urine potassium excretion in both types of mice. Since more Na+ was 
WT (n = 8) TG (n = 8)
Body weight (g) 45.8 ± 3.7 42.7 ± 3.6
Heart weight (mg) 143.1 ± 19.6 148.1 ± 21.9
Heart wt/BW (mg/g) 3.5 ± 0.4 3.1 ± 0.5
Kidney weight (mg) 54.8 ± 12.7 56.1 ± 11.6
Kidney wt/BW (mg/g) 12.0 ± 3.0 13.2 ± 2.6
Adrenal Gland weight 
(mg) 5.0 ± 1.0 4.7 ± 1.0
Adrenal gland wt/BW 
(mg/g) 0.11 ± 0.03 0.11 ± 0.02
Table 1. General Characteristics of hAS+/− and WT Mice. The high expression of hAS gene in hAS+/− mice did 
not affect body weight, adrenal gland weight, heart weight, and kidney weight.
Figure 2. hAS overexpression increased levels of aldosterone in hAS+/− mice. (A) The serum aldosterone levels 
of WT and hAS+/− mice on NS or HS were detected by ELISA. (B) The levels of urine aldosterone were tested 
by ELISA as well. (C) The serum corticosterone levels of WT and hAS+/− mice on NS or HS were measured by 
ELISA. *p < 0.05; **p < 0.01. NS: normal salt diet; HS: high salt diet.
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secreted in HS-fed WT mice, urines from these mice showed significantly higher pH than NS-fed WT and both 
NS- and HS-fed hAS+/− mice.
Furthermore, since both epithelial Na channel (ENaC) and Na+/Cl− co-transporter (NCC) in kidney were 
responsible for Na reabsorption and regulated by aldosterone22, 23, we examined expression levels of these two 
genes in hAS+/− and WT mice (Fig. 4). Again, as expected, in both NS and HS–fed mice, hAS+/− mice showed 
significantly higher expression of three subunits of ENaC in kidney than WT mice. Additionally, HS significantly 
induced ENaC expression in both types of mice. Similarly, hAS+/− mice showed significantly higher expression of 
NCC in kidney than WT mice and HS significantly induced NCC expression in both types of mice.
Suppression of high-salt-induced hypertension in hAS+/− mice by Fadrozole, an aldosterone 
synthase inhibitor. Aldosterone synthase (CYP11B2) inhibition has emerged as a new option for the 
Figure 3. High-salt induced hypertension in hAS+/− mice. (A) On 1 month treatments with HS or NS diets, 
BPs of WT and hAS+/− mice were measured. (B) Continued on HS or NS for a total of 3 months, BPs of WT and 




NS 147 ± 0.51 (5) 151 ± 0.32 (15)†
HS 148 ± 0.51 (5) 152 ± 0.69 (15)§
 K+, mmol/L
NS 4.8 ± 0.06 (5) 4.5 ± 0.07 (15)†
HS 4.88 ± 0.08 (5) 4.0 ± 0.06 (15)*,§
 Renin activity
NS 5.19 ± 0.25 (4) 1.7 ± 0.31 (15)†
HS 285 ± 43.73 (5) 208 ± 16.5 (15)§
Urine
 Na+, mmol/L
NS 125 ± 16.99 (5) 95 ± 8.17 (15)†
HS 285 ± 43.73 (5) 208 ± 16.5 (15)§
 K+, mmol/L
NS 180 ± 20.46 (5) 134 ± 15.97 (15)†
HS 62 ± 11.68 (5) 71 ± 7.16 (15)*,§
 PH
NS 7.0 (5) 6.9 (14)
HS 7.7 (5)# 7.0 (15)
Table 2. Plasma electrolytes and renin activity as well as urinary excreted electrolytes and pH in AS+/− and 
WT mice treated with NS and HS diets. Values are means ± SE and numbers in parentheses represent numbers 
of used animals. *p < 0.05 HS versus NS in AS+/− groups, †p<0.05, AS+/− versus WT with NS; §p<0.05, AS+/− 
versus WT with HS; #p < 0.05, HS versus NS in WTgroups.
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treatment of hypertension. One week treatment of fadrozole (F3806, Sigma), an inhibitor of aldosterone synthase, 
at 4 mg/kg significantly reduced BPs of hAS+/− mice with HS (SBP: 134 ± 6.1 mmHg versus 118 ± 5.5 mmHg, 
p < 0.001; DBP: 109 ± 4.8 mmHg versus 90 ± 5.3 mmHg, P < 0.01, n = 10/group) (Fig. 5). Continued treatment 
Figure 4. Kidney gene expressions and hematocrit in WT and hAS+/− mice. (A,B) hAS+/− (AS-TG) mice 
showed significantly higher gene expressions of the three kidney ENaC subunits encoded by SCNN1a, 
SCNN1b, and SCNN1g compared to WT mice fed with either NS or HS diet. *p < 0.05. (C,D) hAS+/− mice had 
significantly higher gene expressions of the kidney sodium chloride co-transporter as compared to WT mice fed 
with either NS or HS diet. *p < 0.05. (E) HS diet increased hematocrit in hAS+/− but not WT mice. *p < 0.05, 
between AS-TG groups; †p < 0.05, compared to AS-TG Chow group; §p < 0.05, compared to AS-TG HS group.
Figure 5. Fadrozole significantly suppressed high-salt-induced hypertension in hAS+/− mice. hAS+/− 
transgenic mice were fed with HS for 1 month and the BPs were measured. The mice on HS were treated 
continually with fadrozole for 2 months, the BPs of hAS+/− mice were tested at the end of 1 week and 2 months 
treatment of fadrozole respectively. **p < 0.01; ***p < 0.001.
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with fadrozole at this dose for 2 months further reduced BPs of hAS+/− mice with HS (SBP: 110 ± 5.8 mmHg, 
p < 0.001; DBP: 87 ± 8.9 mmHg, P < 0.01: n = 10/group) (Fig. 5).
Discussion
To determine the effects of hAS gene expression on BP, we established a transgenic mouse model that carries 
the human aldosterone synthase gene (cyp11B2) under the control of cyp11B1 promoter. Our study demon-
strates that overexpression of hAS in mice results in significantly higher serum levels of aldosterone and 
high-salt-induced hypertension. We also observe that the high-salt-induced hypertension could be significantly 
reduced by the AS inhibitor, fadrozole, in these mice. These data suggest that AS overexpression plays the signifi-
cant role in high dietary salt-induced BP in these mice.
Hypertension is one of the most important preventable causes of premature morbidity and mortality in the 
developed world. It is a key risk factor for ischemic and hemorrhagic stroke, myocardial infarction, heart failure, 
chronic kidney disease, and cognitive decline24. Aldosterone is a major mineralocorticoid hormone that plays a 
key role in the regulation of electrolyte balance and blood pressure. Excess aldosterone levels can arise from dys-
regulation of the renin-angiotensin-aldosterone system and are implicated in the pathogenesis of hypertension, 
chronic kidney disease and heart failure. It has been shown that aldosterone regulates Na+ conservation in the 
distal nephron through multiple mechanisms that modulate the activity of the epithelial Na+ channel (ENaC) 
including rapidly transcriptionally up-regulating the ENaCα subunit and indirectly regulating the ubiquitination 
of ENaC subunits22. Genetic deletion or loss-of-function mutations in the channels leads to Na wasting and hypo-
tension, while conversely, hyperactivity of the channels causes Na retention and hypertension25, 26. Additionally, 
Na+ reabsorption is mediated by Na+/Cl− co-transporter (NCC) that is also under the influence of aldosterone23. 
In this study, on either NS or HS diet, interestingly, expressions of three ENaC subunits and NCC in kidneys of 
the AS+/− mice were significantly increased, accompanied by increased plasma aldosterone. The considerably 
increased BP of the AS+/− mice on the HS diet probably results from a substantially increase in sodium reab-
sorption in the distal nephron consequent to the markedly increased expression of ENaC and NCC induced by 
elevated plasma aldosterone in these mice27.
In the AS+/− mice, we observed markedly expressions of AS in brain. It is quite possible that HS-induced HP 
in the AS+/− mice also results from an increased expressions of brain aldosterone. It has been shown that intrac-
erebroventricular (icv) infusion of aldosterone does not change renal sympathetic nerve activity (RSNA), BP, or 
HR. However, modestly higher Na+ concentrations induce significant sympathetic and blood pressor responses28. 
It has been suggested that increased synthesis of aldosterone in the central nervous system contributes to salt sen-
sitivity of BP by activation of its downstream receptor (mineralocorticoid receptor (MR))-epithelial Na+ channel 
(ENaC)-endogenous ouabain (EO) pathway28.
Aldosterone’s downstream MR blockers such as spironolactone and eplerenone block the actions of aldoster-
one at the receptor level. Clinical trials indicate that spironolactone and eplerenone effectively lower BP, particu-
larly in resistant hypertension, and improving outcomes in congestive heart failure29–34. However, use of these 
agents, particularly spironolactone, can be limited by adverse effects, and is associated with reactive increases in 
circulating aldosterone levels that theoretically exacerbate the detrimental actions of aldosterone35–37. Therefore, 
inhibition of aldosterone synthesis in hypertension treatments represents a novel approach to decreasing expo-
sure of the cardiovascular system to aldosterone, which may prove advantageous in terms of tolerability and/or 
cardiovascular and renal protection.
Aldosterone synthase (cytochrome P450 11B2, CYP11B2) is the sole enzyme responsible for the production 
of aldosterone in humans38 and recently was assumed to be a therapeutic target for aldosterone-related HP treat-
ments. Recently, several approaches have been made to generate AS transgenic mice; however, these mice did not 
show the high-salt-induced hypertension phenotype. One transgenic mouse line overexpressed AS in the heart, 
showing coronary dysfunction but no difference of blood pressure between these mice and wild type mice16. 
Another mouse line (AShi/hi) was generated by replacing the 3′ untranslated region of AS mRNA with that from 
a stable mRNA17. Plasma aldosterone did not differ significantly between WT and AShi/hi on the normal-salt diet 
but was significantly higher in AShi/hi than WT mice on the high-salt diet. The BP was modestly but significantly 
increased by10 mmHg in AShi/hi on the high-salt diet as compared to WT mice on the high-salt diet. It was noted 
that the BP was not significantly induced in AShi/hi on the high-salt diet as compared to AShi/hi on the normal-salt 
diet and the BP induced by the high-salt diet remained within the normal range (<120 mmHg,). In contrast, our 
hAS+/− mice showed much higher serum level of aldosterone when they were fed with NS (~2 folds) and HS (~18 
folds) as compared to WT mice fed with the same food. The BP in hAS+/− mice on the HS diet was not only sig-
nificantly increased as compared to WT mice on the HS diet, but also markedly induced as compared to the NS 
diet (135 vs. 100 in a one-month treatment and 137 vs. 104 in a three-month treatment). Nonetheless, this exper-
imental AS mouse model appears to be more acceptable for future aldosterone-related hypertension research. 
Additionally, similar to Primary Hyperaldosteronism usually with lower hematocrit39, there were slightly but 
significant reduced hematocrit in NS fed hAS+/− mice as compared to NS fed mice. Interestingly, consistent to the 
previous report40, HP induced by HS was accompanied with significantly increased hematocrit in hAS+/− mice as 
compared to WT mice without induced HP.
We have for the first time demonstrated that hAS overexpression in Tg mice was involved in aldosterone over-
expression and high salt-induced mouse HP. hAS was highly expressed in adrenal glands and hAS overexpression 
increased levels of aldosterone in hAS+/− mice. Under the normal salt condition, the increase in hAS expression 
in the hAS+/− mice had no significant effects on BP. In contrast, with high salt diet, BP of hAS+/− mice was mark-
edly increased as compared to wild type and normal salt-treated hAS+/− mice. Additionally, we demonstrated that 
fadrozole treatments at 4 mg/kg, the effective dose that was used for blocking AS activity in vivo41 significantly 
reduced the elevated BPs in the high salt-treated hAS+/− mice. Our results suggest that this mouse model with 
hAS overexpression could be an appropriate animal model for AS and aldosterone overexpression/PA related 
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hypertension study. Aldosterone synthesis may be an ideal pharmacological therapy target for aldosterone-related 
hypertension.
Methods
Vector Construction and Generation of Transgenic Mouse Lines. We set up a mouse colony by per-
forming vasectomy, pronuclear injection of the CYP11B1-hAS fragment containing the human cyp11B1 pro-
moter (pCYP11B1 (−2015–+3))18 and the human hAS coding sequence (cDNA, +4–+1515) (Fig. 1A) into a 
CH3 donor zygote, transfer of injected zygotes into recipient foster CH3 mice, as well as screening of offspring 
by Southern blot analysis of tail DNA to identify a mouse founder line. Transgenic offspring from each line were 
determined by PCR analysis of tail DNA using the following primers specific for hAS: 5′-GTG GCG TGT TCT 
TGT TGA ATG-3′ and 5′-GGT GGA TTT GAA CAT GAC CTC-3′ (generating a 300-bp product). All subse-
quent analyses were performed with heterozygous transgenic mice.
Mice. Mice were bred in the laboratory of Animal Center at Indiana University School of Medicine. Mice 
were housed 3–5 per cage, fed with food and water ad libitum, and maintained in a 12-h light/dark cycle facility. 
Animal protocols pertinent to this study were approved by the Indiana University School of Medicine Laboratory 
Animal Resource Center.
RNA isolation, reverse transcription-PCR. Total RNA was extracted using RNeasy mini kit (Qiagen, 
Valencia, CA, USA) and reverse transcribed by M-MLV (Invitrogen, Carlsbad, CA, USA). Derived comple-
mentary DNAs were amplified using PCR master mix (Promega, Madison, WI, USA). Primer sequences for 
hAS were as follow: 5′-GTG GCG TGT TCT TGT TGA ATG-3′ and 5′-GGT GGA TTT GAA CAT GAC CTC-
3′. β-actin was amplified as a reference gene with primers 5′-ACCGCTCGTTGCCATTAGTGATGA-3′ and 
5′-AAGGCCAACCGTGAAAAGATGACC-3′.
Quantification of Aldosterone and Corticosterone in serum and urine by ELISA 
assay. Aldosterone levels in serum and urine and corticosterone levels in serum were measured using 
enzyme-linked immunosorbent assay (ELISA) kits (Aldosterone: ab136933, Abcam, Cambridge, MA; 
Corticosterone: 55-CORMS-E01, Alpco, Salem, NH), according to the manufacturer’s instructions.
BP measurements. Mean systolic (SBP) and diastolic blood pressures (DBP) of conscious mice were meas-
ured using a CODA tail-cuff non-invasive blood pressure system (Model CODA6, Kent Scientific, Torrington, 
CT) following the manufacturer’s specifications. Before measurement, animals were conditioned by exposed to 
the environment and instrument on a daily basis for a week. A warmed restraining chamber was used to maintain 
mice, an inflatable occlusion cuff was placed around the mouse tail, as well as a volume pressure recording cuff 
was used according to the manufacturer’s specifications to measure arterial systolic pressure, arterial diastolic 
pressure, and heart rate. The blood pressure of trained mice was monitored starting at 2 pm for 30–40 min and 
the mean value of 5 final readings were obtained after 15 initial consecutive readings whose values were within 
5% of the mean. Basal blood pressure was determined in NS mice fed with a normal diet containing 0.2% NaCl 
(Harlan Teklad, 2018) and HS mice that were switched to a high salt diet (high-salt chow containing 4% NaCl, 
Harlan Teklad, 2018) allowed to equilibrate at least for 1 week on the diet. Mice were allowed free access to tap 
water at all times.
Statistical Analysis. One-way analysis of variance (ANOVA) was used for statistical analyses and compar-
isons for the differences between groups. All data are expressed as mean ± standard error of the mean (SEM). 
Differences between two means were considered significant when p was at least equal or less than 0.05.
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